Text Size
794 studies found for:    kidney cancer | Open Studies | Exclude Unknown

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting AMG 172 First in Human Study in Patients With Kidney Cancer
Conditions: Renal Cell Adenocarcinoma;   Clear Cell Renal Carcinoma;   Clear Cell Renal Cell Carcinoma;   Renal Cell Carcinoma
Intervention: Drug: AMG 172
2 Recruiting Autoantibody Blood Test in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer
Condition: Kidney Cancer
Interventions: Genetic: gene expression analysis;   Genetic: protein expression analysis;   Other: diagnostic laboratory biomarker analysis;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method
3 Recruiting Interleukin-2 in Metastatic Kidney Cancer
Conditions: Renal Cell Cancer Metastatic;   Kidney Cancer Metastatic
Intervention: Drug: Interleukin-2
4 Recruiting Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC)
Conditions: Advanced Renal Cell Carcinoma;   Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma
Interventions: Drug: Standard Treatment;   Biological: AGS-003
5 Recruiting Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer
Conditions: Metastatic Kidney Cancer;   Metastatic Renal Cell Carcinoma
Intervention: Other: Serum and urinary CA9 level
6 Recruiting Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Condition: Kidney Cancer
Interventions: Drug: gemcitabine hydrochloride;   Drug: sunitinib malate
7 Recruiting A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer
Conditions: HLRCC;   Metastatic Papillary RCC
Interventions: Drug: Bevacizumab;   Drug: Erlotinib
8 Not yet recruiting Carfilzomib in Refractory Renal Cell Carcinoma (RCC)
Condition: Kidney Cancer
Intervention: Drug: Carfilzomib
9 Recruiting Immediate Surgery or Surgery After Sunitinib Malate in Treating Patients With Metastatic Kidney Cancer
Condition: Kidney Cancer
Interventions: Procedure: timing of surgery;   Genetic: gene expression analysis;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis;   Procedure: therapeutic conventional surgery
10 Recruiting Phase II Study of Vandetanib in Individuals With Kidney Cancer
Conditions: Renal Cancer;   Von Hippel Lindau
Intervention: Drug: ZACTIMA (Vandetanib) (ZD6474)
11 Recruiting Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery
Condition: Kidney Cancer
Interventions: Drug: everolimus;   Other: placebo
12 Recruiting Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer
Conditions: Renal Cell Carcinoma;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Genetic: mutation analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced magnetic resonance imaging;   Drug: sunitinib malate;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis
13 Recruiting A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology
Conditions: Carcinoma, Renal Cell;   Renal Cell Carcinoma With Clear Cell Histology;   Renal Cell Carcinoma With Non-Clear Cell Histology;   Renal Cell Carcinoma of Papillary Histology
Intervention: Drug: AGS-16C3F
14 Recruiting Mechanism of Action of High-Dose IL-2 (Aldesleukin) in Metastatic Melanoma and Kidney Cancer
Conditions: Metastatic Melanoma;   Renal Cell Cancer
Intervention: Biological: aldesleukin
15 Recruiting Ziv-Aflibercept in Treating Patients With Metastatic or Unresectable Kidney Cancer
Conditions: Clear Cell Renal Cell Carcinoma;   Recurrent Renal Cell Cancer;   Stage III Renal Cell Cancer;   Stage IV Renal Cell Cancer
Interventions: Biological: ziv-aflibercept;   Other: laboratory biomarker analysis
16 Not yet recruiting Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
Conditions: Recurrent Renal Cell Cancer;   Stage IV Renal Cell Cancer;   Type 1 Papillary Renal Cell Carcinoma;   Type 2 Papillary Renal Cell Carcinoma
Intervention: Drug: pazopanib hydrochloride
17 Recruiting Sunitinib Before and After Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed By Surgery
Condition: Kidney Cancer
Interventions: Drug: sunitinib malate;   Genetic: gene expression analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Genetic: western blotting;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
18 Recruiting Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer
Conditions: Leiomyomatosis;   Kidney Neoplasms
Intervention:
19 Recruiting Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer
Conditions: Renal Cell Carcinoma;   Graft-Versus-Host Disease;   Engraftment Syndrome
Interventions: Drug: Pentostatin;   Drug: Sirolimus;   Drug: Cyclophosphamide;   Procedure: Allogeneic Hematopoietic Stem Cell Transplant;   Procedure: Th2 Cell Transplantation;   Drug: Th2 Cells in Allogeneic HSCT
20 Recruiting Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery
Conditions: Clear Cell Renal Cell Carcinoma;   Stage IV Renal Cell Cancer
Interventions: Drug: pazopanib hydrochloride;   Other: placebo;   Procedure: quality-of-life assessment;   Other: questionnaire administration;   Other: pharmacological study
To Top

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
† Indicates status has not been verified in more than two years